CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
1 . A method for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
2 . The method according to claim 1 , wherein the pharmaceutically acceptable salt of cyclobenzaprine in the pharmaceutical composition is cyclobenzaprine HCl.
3 . (canceled)
4 . The method according to claim 2 , wherein the cyclobenzaprine HCl is in the form of a mannitol eutectic.
5 . (canceled)
6 . The method according to claim 4 , wherein the mannitol eutectic is selected from the group consisting of a 75%±2% cyclobenzaprine HCl and 25%±2% β-mannitol eutectic, a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, a mixture of a 75%±2% cyclobenzaprine HCl and 25%±2% β-mannitol and a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, and a granule comprising an outer layer of a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic and an inner layer of β-mannitol.
7 . The method according to claim 4 , wherein the pharmaceutical composition comprising the cyclobenzaprine HCl or the eutectic thereof further comprises a basifying agent.
8 . The method according to claim 7 , wherein the basifying agent is selected from a group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.
9 . (canceled)
10 . The method according to claim 1 , wherein the pharmaceutical composition comprises:
(i) between 0.1 mg and 30 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof;
(ii) between 1 mg and 20 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof;
(iii) less than 10 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof,
(iv) less than 5 mg of cyclobenzaprine or a pharmaceutically acceptable salt thereof,
(v) between about 2.8 mg to about 5.6 mg of cyclobenzaprine HCl;
(vi) about 5.6 mg of cyclobenzaprine HCl; or
(vii) about 2.8 mg of cyclobenzaprine HCl.
11 .- 16 . (canceled)
17 . The method according to claim 10 , wherein the pharmaceutical composition is administered simultaneously or sequentially in two dosage units, and wherein:
(i) tithe combined amount of the cyclobenzaprine HCl in the two dosage units is about 5.6 mg; or
(ii) each dosage unit comprises about 2.8 mg of cyclobenzaprine HCl.
18 . (canceled)
19 . The method according to claim 1 , wherein the pharmaceutical composition is administered daily.
20 - 21 . (canceled)
22 . The method according to claim 1 , wherein the pharmaceutical composition is formulated for sublingual, buccal, intranasal, oral, intravenous, intramuscular, subcutaneous, inhalational, transdermal, rectal, vaginal, parenteral or palatal administration and wherein the pharmaceutical composition is formulated as a tablet, a thin film or a suppository.
23 .- 24 . (canceled)
25 . The method according to claim 1 , wherein the pharmaceutical composition is administered for at least 14 weeks.
26 . The method according to claim 1 , wherein the subject has tested positive for SARS-CoV-2 infection at least three months prior to administration of the pharmaceutical composition.
27 . The method according to claim 1 , wherein the one or more symptoms associated with the PASC is neurologic, non-neurologic, systemic, or a combination thereof.
28 . The method according to claim 1 , wherein the one or more symptoms associated with the PASC is selected from the group consisting of fatigue, malaise, pain, muscle weakness, diaphoresis, chills, limb edema, dizziness, cognitive dysfunction, respiratory symptoms, cardiovascular abnormalities, alopecia, olfactory abnormalities, psychosocial symptoms, and abdominal symptoms.
29 . The method according to claim 28 , wherein:
(i) the respiratory symptoms are independently selected from the group consisting of polypnea, chest pain, cough, sputum, sore throat, throat pain, abnormal breathing, and shortness of breath;
(ii) the cognitive dysfunction is characterized by brain fog characterized by one or more of a memory problem, a concentration problem, a lack of mental clarity, or an inability to focus;
(iii) the psychosocial symptoms are independently selected from the group consisting of sleep disturbance, depression, anxiety, feelings of inferiority, and worse quality of life, and wherein the sleep disturbance is independently selected from the group consisting of insomnia, difficulty falling asleep, vivid or lucid dreams, and nonrestorative sleep;
(iv) the malaise is post-exertional malaise; or
(v) the pain is independently selected from the group consisting of multi-site pain, diffuse myalgia, arthralgia, musculoskeletal pain, headaches, facial pain, chest pain, abdominal pain, back pain, joint pain, body ache, lumbago with sciatica, low back pain, and pain in one or more of limb, hand, foot fingers, or toes.
30 .- 35 . (canceled)
36 . The method according to claim 29 , wherein:
(i) the one or more symptoms associated with the PASC is multi-site pain;
(ii) the one or more symptoms associated with the PASC are multi-site pain and fatigue;
(iii) the one or more symptoms associated with the PASC are multi-site pain and insomnia; or
(iv) the one or more symptoms associated with the PASC are multi-site pain, fatigue, and insomnia.
37 .- 39 . (canceled)
40 . The method according to claim 36 , wherein:
(i) the multi-site pain affects at least 4 regions of the body;
(ii) the multi-site pain regions are assessed using a Michigan Body Map; and
(iii) the multi-site pain region is selected from one or more of the regions of a Michigan Body Map including left arm, right arm, left leg, right leg, front of trunk, back of trunk, or head.
41 .- 42 . (canceled)
43 . The method according to claim 27 , wherein the one or more symptoms associated with the PASC is new onset, follows initial recovery from an acute (SARS)-CoV-2 infection, persists post-(SARS)-CoV-2 infection, or persists post-discharge from in-patient care in a hospital, clinic or other medical facility following admission for (SARS)-CoV-2 infection.
44 .- 53 . (canceled)
54 . The method according to claim 1 , wherein the one or more symptoms associated with the PASC is assessed by a Numerical Rating Scale (NRS), a Patient Global Impression of Change (PGI-C), a PROMIS scale, a Sheehan Disability Scale (SDS), a Post-COVID-19 Functional Status (PCFS) scale, an Insomnia Severity Index (ISI), an Epworth Sleepiness Scale (ESS), or a combination thereof.
55 . (canceled)
56 . The method according to claim 1 , wherein the subject is human.